Biocept: Darrell Taylor
Biocept has appointed Darrell Taylor as senior VP, general counsel, and chief compliance officer. He was most recently CCO for Precision Diagnostics. He also held leadership positions in the clinical laboratory operations of Laboratory Corporation of America and at various hospitals.
Sixth Street: Jennifer Doudna
Jennifer Doudna has become chief science adviser of investment firm Sixth Street. She is the director of the Innovative Genomics Institute and a professor of chemistry, biochemistry and molecular biology, and biomedicine and health at the University of California, Berkeley. In 2020, Doudna was awarded the Nobel Prize in Chemistry along with collaborator Emmanuelle Charpentier for their discovery of CRISPR gene editing.
PreludeDx: Derek Maetzold
PreludeDx has appointed Derek Maetzold to its board of directors. Maetzold founded Castle Biosciences, serving as president, CEO, and a board member since its inception in 2007. He co-invented several Castle technologies and has contributed to the development and commercialization of five diagnostic and prognostic cancer tests.
Prior to Castle, Maetzold spent 24 years in pharma, holding leadership roles at Encysive Pharmaceuticals (acquired by Pfizer), Schering-Plough (now Merck), Integrated Communications (now FCB Health), Amylin Pharmaceuticals (now owned by AstraZeneca), and Sandoz Pharmaceuticals (now a division of Novartis).
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.